"Drugs, Investigational" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
| Descriptor ID |
D015507
|
| MeSH Number(s) |
D26.371
|
| Concept/Terms |
Drugs, Investigational- Drugs, Investigational
- Investigational New Drugs
- Drugs, Investigational New
- New Drugs, Investigational
- Investigational Drugs
|
Below are MeSH descriptors whose meaning is more general than "Drugs, Investigational".
Below are MeSH descriptors whose meaning is more specific than "Drugs, Investigational".
This graph shows the total number of publications written about "Drugs, Investigational" by people in this website by year, and whether "Drugs, Investigational" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drugs, Investigational" by people in Profiles.
-
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 09; 19(9):727-737.
-
Venanzi Rullo E, Ceccarelli M, Condorelli F, Facciol? A, Visalli G, D'Aleo F, Paolucci I, Cacopardo B, Pinzone MR, Di Rosa M, Nunnari G, Pellican? GF. Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review). Mol Med Rep. 2019 Mar; 19(3):1987-1995.
-
Moerdler S, Zhang L, Gerasimov E, Zhu C, Wolinsky T, Roth M, Goodman N, Weiser DA. Physician perspectives on compassionate use in pediatric oncology. Pediatr Blood Cancer. 2019 03; 66(3):e27545.
-
Malatack JJ, Doyle D. A Drug Regimen for Progressive Familial Cholestasis Type 2. Pediatrics. 2018 01; 141(1).
-
Hanley CM, Robinson VM, Kowey PR. Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms. Circ Arrhythm Electrophysiol. 2016 Mar; 9(3):e002479.
-
Pucci MJ, Bush K. Investigational antimicrobial agents of 2013. Clin Microbiol Rev. 2013 Oct; 26(4):792-821.
-
Wang TY, Angiolillo DJ, Cushman M, Sabatine MS, Bray PF, Smyth SS, Dauerman HL, French PA, Becker RC. Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol. 2012 Mar 6; 59(10):891-900.
-
Kowey PR. Thoroughly measuring the QT interval: can we find the shortcuts? Heart Rhythm. 2011 Nov; 8(11):1786-7.
-
Bielory L. American Academy of Allergy, Asthma and Immunology (AAAAI)-2010 annual meeting. 26 February-2 March 2010, New Orleans, LA, USA. IDrugs. 2010 May; 13(5):304-7.
-
Sanoski CA. Understanding atrial fibrillation and new therapeutic advances to improve its management: introduction. Am J Health Syst Pharm. 2010 May 1; 67(9 Suppl 5):S3-4.